TEICHOS LABORATORIES, LLC

West Lafayette, IN · Biotech · Private

Synthetic peptidoglycan (sPGN) immune tolerance molecules, specifically TL-003, for tolerizing vaccine therapy against Factor VIII resistance in Hemophilia A.

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
West Lafayette, IN
Total capital
$1.1M
Federal grants
$503K
2 awards · 2021–2022
Rank in peer group#248 of 502
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$600K
2 awards · Health and Human S
Rank in Biotech#218 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

202120222023FEDERAL ↑EQUITY ↓Cumulative $1.1M$243K$300K$260K$300K
202120222023FEDERAL ↑EQUITY ↓Cumulative $1.1M$243K$300K$260K$300K

Latest events

  • Federal contractHealth and Human S · Teichos Laboratories, Llc. "augmenting The Quality And Duration Of The Immune Response With A Novel TLR2 Agonist-aluminum Combination Adjuvant".$300K
  • Federal grantHealth and Human S · Phase I · Immunotherapy for Factor VIII Inhibition in Hemophilia A$260K
  • Federal contractHealth and Human S · The Proposal, Entitled Augmenting The Quality And Duration Of The Immune Response With A Novel TLR2 Agonist-aluminum Combination Adjuvant, Was Submitted By Teichos Laboratories, Llc, West Lafayette, In, With Dr. Larry Chris Blaszczak As The Pi. The O$300K
  • Federal grantHealth and Human S · Phase I · A Totally Synthetic Immunostimulator that Targets Toll-like Receptor 2 and NOD2: Toward Improved Influenza Vaccines$243K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

  • Federal grants#248 · top 49%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • iXpressGenes, Inc.Similar federal contract value in Biotech · $614K in contracts
  • NEUCYTE INCSimilar federal contract value in Biotech · $602K in contracts
  • Proteovista LLCSimilar federal contract value in Biotech · $600K in contracts
  • TENDEL THERAPIES INCSimilar federal contract value in Biotech · $600K in contracts
  • EVIMERO, LLCSimilar federal contract value in Biotech · $597K in contracts
  • Protein Innovation Labs, Inc.Similar federal contract value in Biotech · $586K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .